AveXis Inc. (NASDAQ:AVXS) shares saw unusually-high trading volume on Wednesday . Approximately 184,664 shares were traded during trading, a decline of 12% from the previous session’s volume of 209,132 shares.The stock last traded at $39.68 and had previously closed at $36.01.

AVXS has been the subject of several recent analyst reports. Zacks Investment Research lowered AveXis from a “hold” rating to a “sell” rating in a research note on Wednesday, June 1st. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of AveXis in a research note on Monday, May 9th. Goldman Sachs Group Inc. increased their price objective on AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research note on Friday, May 13th. Wells Fargo & Co. initiated coverage on AveXis in a research note on Friday, July 15th. They set a “market perform” rating for the company. Finally, Jefferies Group lowered AveXis from a “buy” rating to a “hold” rating and increased their price objective for the stock from $39.00 to $42.00 in a research note on Wednesday, June 22nd. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. AveXis presently has a consensus rating of “Buy” and an average price target of $43.80.

The firm’s market capitalization is $900.28 million. The firm’s 50 day moving average price is $40.13 and its 200 day moving average price is $30.73.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.89. Equities research analysts predict that AveXis Inc. will post ($3.65) EPS for the current year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.